Abstract:Objective To analyze the effects of budesonide and terbutaline combined with methylprednisolone on clinical symptoms, D-dimer (D-D) level and lung function in children with lobar pneumonia (LP). Methods The clinical data of 94 children with LP who were treated in our hospital from October 2022 to August 2023 were retrospectively collected. Children were divided into control group (budesonide and terbutaline treatment, 47 cases) and observation group (budesonide and terbutaline combined with methylprednisolone treatment, 47 cases). Clinical efficacy, duration of clinical symptom resolution, lung function [TPTEF/TE], VPTEF/VE, tidal volume (Vt/kg)], serum related factors [interleukin-6 (IL-6), D-D] levels and adverse reactions were collected and compared between the two groups. Results The total effective rate of observation group was significantly higher than that of control group (P < 0.05). After treatment, the disappearance time of rales, lung shadow absorption time, fever reduction time, cough and wheezing time of clinical symptoms in the observation group were significantly shorter than those in the control group (P < 0.05). After treatment, the levels of VPTEF/VE, TPTEF/TE and Vt/kg in both groups were significantly higher than before treatment, and the levels of VPTEF/VE, TPTEF/TE and Vt/kg in the observation group were significantly higher than those in the control group (P < 0.05). After treatment, the D-D and IL-6 levels in both groups were significantly lower than before treatment, and the D-D and IL-6 levels in the observation group were significantly lower than those in the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Budesonide and terbutaline combined with methylprednisolone in the treatment of LP children can improve the efficacy, relieve clinical symptoms, regulate lung function, reduce inflammation in vivo, and have high safety.